CeriBell Reports Q3 Revenue Growth and Raises 2026 Guidance
CeriBell reported third-quarter revenue of $29.3 million, up 30% year over year, with a net loss of $21.4 million and an Adjusted EBITDA loss of $12.1 million. It raised full-year 2026 revenue guidance to $115 million–$117 million.
Story updates
10:51:27 PM UTC
SquawkNews
*-- GUIDANCE: (CBLL) CeriBell Expects 2026 Revenue Range $115M - $117M, vs. FactSet Est of $115.5M
CeriBell, Inc. reported total revenue of $29.3 million for the third quarter ended September 30, 2026, a 30% increase compared to the same period in 2025. The company reported a net loss of $21.4 million and an Adjusted EBITDA loss of $12.1 million for the quarter. Following these results, CeriBell raised its full-year 2026 revenue guidance to a range of $115 million to $117 million.
The company continues to focus on its point-of-care EEG platform for acute care settings.